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Objective. The purpose of this study was to describe the epidemiology of coinfection with hepatitis C virus (HCV) and HIV among
a cohort of pregnant Thai women. Methods. Samples from 1771 pregnant women enrolled in three vertical transmission of HIV
studies in Bangkok, Thailand, were tested for HCV. Results. Among HIV-infected pregnant women, HCV seroprevelance was 3.8%
andtheactiveHCVinfectionratewas3.0%.AmongHIV-uninfectedpregnantwomen,0.3%wereHCV-infected.Intravenousdrug
use by the woman was the factor most strongly associated with HCV seropositivity. Among 48 infants tested for HCV who were
born to HIV/HCV coinfected women, two infants were HCV infected for an HCV transmission rate of 4.2% (95% 0.51–14.25%).
Conclusions. HCV seroprevalence and perinatal transmission rates were low among this Thai cohort of HIV-infected pregnant
women.
Copyright © 2008 Denise J. Jamieson et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Worldwide, the hepatitis C virus (HCV) seroprevalence rate
among pregnant women is approximately 1% [1]. This is
similar to the 1.6% prevalence of HCV antibody in the
general population in the United States [2]. Among HIV-
infected pregnant women, much higher prevalences of HCV
positivity have been reported, ranging from as high as 30 to
50% in some settings [3, 4], particularly in populations with
high rates of injection drug use.
Although the perinatal transmission rate of HCV is
estimated to be less than 5% among HIV-uninfected women,
it is generally higher in HIV-infected women [1]. Not all
studies, however, have found increased HCV transmission
rates among HIV-infected women [5] and a wide range of
estimates of the risk of vertical transmission of HCV among
coinfected women has been reported with wide geographic
variation [6, 7].
The purpose of this study was to describe the epidemiol-
ogy of coinfection with hepatitis C virus and HIV among a
cohort of pregnant Thai women.
2. MATERIALS AND METHODS
The current study population includes 1771 women pre-
viously enrolled in three vertical transmission studies in
Bangkok, Thailand [8–10] who had specimens available
for HCV testing. From the ﬁrst study (peri-1), 342
HIV-uninfected women and 293 HIV-infected women are
included. From the second (peri-2) and third studies
(peri-3), 391 and 745 HIV-infected women are included,
respectively. Women in these studies were either enrolled2 Infectious Diseases in Obstetrics and Gynecology
during antenatal care (peri-1 and 2) or at delivery (peri-
3). All children born to HIV-infected women were followed
for 4–18 months and their mothers did not breastfeed. No
follow-up information is available for infants born to HIV-
uninfected women in peri-1. Peri-1 was an observational
prospective cohort study without treatment interventions,
peri-2 was a randomized placebo-controlled clinical trial
assessing the eﬃcacy of short-course zidovudine prophylaxis
antenatally and intrapartum, and peri-3 was an observa-
tional study of short-course zidovudine and single-dose
nevirapine propylaxis. All three studies were conducted
jointly by the Thailand Ministry of Public Health and the
U.S. Centers for Disease Control and Prevention (CDC) at
two large Bangkok hospitals from 1992 to 2004. The three
perinatal studies (peri-1,2,3) and this current retrospective
laboratorystudywereallapprovedbytheinstitutionalreview
boards at the CDC in Atlanta and the Ethical Review
Committees for Research in Human Subjects at the Thailand
Ministry of Public Health and Siriraj Hospital in Bangkok.
In the original studies, specimens were collected and
tested for HIV, HIV viral load, CD4 count as previously
described [8, 9]. Stored plasma specimens from pregnancy
or delivery were screened for antibodies to HCV (anti-
HCV) using enzyme immunoassay (EIA; Abbott Murex
version 4.0, Abbott Laboratories, Abbott Park, Ill USA).
All positive EIAs were tested with qualitative reverse tran-
scriptase polymerase chain reaction (RT-PCR; Ampliscreen,
Roche Diagnostic Systems, Branchburg, NJ, USA). If the
qualitative RT-PCR was negative, the plasma specimen was
retested with recombinant immunoblot assay (RIBA 3.0,
Chiron Corporation, Emeryville, Calif, USA). All women
who were EIA positive and either qualitative RT-PCR or
RIBA positive are considered HCV infected (either current
orpast);allotherwomenareconsideredHCVuninfected.All
specimenswithdetectablevirusweretestedwithquantitative
PCR (COBAS Amplicor HCV Monitor Test, version 2.0,
Roche Diagnostic Systems) with a lower limit of detection
of <600 copies/mL. All women with detectable virus are
considered to have active HCV infection. Specimens with
detectable HCV were genotyped using the Trugene HCV
5 NC genotyping kit (Bayer HealthCare LLC, Berkeley,
Calif, USA) and sequence analysis with the OpenGene
DNA sequencing system. Results were then conﬁrmed
using sequence analysis (ABI PRISM 310 Genetic Analyzer,
Applied Biosystems, Calif, USA) methods. In 8 cases where
the results from the two techniques were discordant, the
715 nt E1-E2 region at position 883-1597 nt was directly
sequenced.
Stored plasma from infants born to women coinfected
with HIV and HCV was also tested for HCV. An HCV-
infected infant was deﬁned as an infant who was anti-HCV
positive (i.e., EIA-positive with conﬁrmatory RIBA) at 18
monthsofageorolderorwhohadpositiveHCVRNAontwo
occasions. Several serial samples from infants were tested,
dependingonavailabilityofsamplesandtestingresults,since
HCV infection often cannot be excluded in infants by one-
time testing [11]. However, due to limited availability infant
specimens,18/48(37.5%)ofinfantstestedhadtestingatonly
one time point.
Statistical analyses were performed using SAS software
version 9.1 (SAS Institute, Cary, NC, USA). Odds ratios
with 95% conﬁdence intervals were estimated using uncon-
ditional logistic regression, adjusting for the three perinatal
studies. Ninety-ﬁve percent conﬁdence intervals for HCV
transmission rates were estimated using exact binomial
methods.
3. RESULTS
There were low rates of intravenous drug use (1.5%) among
the 1771 women included in this study (Table 1). A higher
proportion of women reported several other risk factors for
hepatitis C acquisition, including having an injection drug-
using partner (10.2%) and ever having been a commercial
sex worker (7.8%). HIV-infected women had moderately
highCD4countsatdelivery(mean428cells/mm3);themean
viral load at delivery was 10000 copies/mL.
Among 1429 HIV-infected pregnant women 62 (4.3%)
were found to have HCV antibodies by EIA. Of those, 54 had
positive conﬁrmatory testing by either RT-PCR (n = 43) or
by RIBA (n = 11). Thus, 3.8% (54/1429) of HIV-infected
pregnant women were found to be coinfected with HCV
and 3.0% (43/1429) had evidence of active infection. Among
342 HIV-uninfected women, 2 (0.6%) were found to have
HCV antibodies by EIA. Of those, only one of the women
had positive conﬁrmatory testing by RT-PCR. Thus, 0.3%
(1/342) of HIV-uninfected pregnant women were found to
be infected with HCV.
Among the 54 HCV-seropositive women, 22 did not
receive any antiretroviral prophylaxis, 22 received 4 weeks of
antenatal zidovudine and intrapartum zidovudine, and 10
received 4 weeks of antenatal zidovudine and intrapartum
zidovudine and nevirapine. Of the 43 HIV-infected women
with quantiﬁable HCV, the serum levels of HCV RNA
were as follows: 12 women with <100000 copies/mL, 17
women with 100000–850000 copies/mL, and 13 women
with >850000 copies/mL. One woman who was HCV RNA-
PCR positive on the qualitative assay had undetectable
virus (<600 copies/mL) on the quantitative assay. The HIV-
uninfected woman with quantiﬁable HCV had a serum level
of HCV of 62000 copies/mL. The HIV-infected women in
later cohorts (peri-2 and peri-3) were more likely to be HCV
infected (4.1 and 4.4%, resp.) compared with HIV-infected
women in the earlier cohort (1.7%) (see Table 1). Among the
35 HCV-infected women with conﬁrmed HCV genotyping
results, 14 (40%) were genotype 3a, 14 (40%) were genotype
1a, 4 (11.4%) were genotype 1b, 2 (5.7%) were genotype 6a,
and 1 (2.9%) was genotype 4a.
In unadjusted analyses, factors associated with pregnant
women being HCV infected included more education,
intravenous drug use, having a partner with a history of
injection drug use, ever having been a commercial sex
worker, and having received a blood transfusion. These risk
factors remained signiﬁcant when adjusting for perinatal
study (Table 2). In a multivariate model adjusted for all
covariates in Table 2, only three factors remained signiﬁcant:
intravenous drug use (adjusted odds ratio 70.5; 95% CI
24.8–201), having a partner with a history of injection drugDenise J. Jamieson et al. 3
Table 1: Demographic and clinical characteristics of 1771 women enrolled in 3 vertical transmission HIV studies in Bangkok, Thailand,
1992–2004 (n (%)).
Peri-1
(HIV−)
(n = 342)
Peri-1
(HIV+)
(n = 293)
Peri-2
(n = 391)
Peri-3
(n = 745)
Total
(n = 1771)
HCV status
Infected 1 (0.3) 5 (1.7) 16 (4.1) 33 (4.4) 55 (3.1)
Uninfected 341 (99.7) 288 (98.3) 375 (95.9) 712 (95.6) 1716 (96.9)
Education
Primary or less 227 (66.4) 197 (67.2) 225 (57.5) 418 (56.1) 1067 (60.3)
Greater than primary 115 (33.6) 96 (32.8) 166 (42.5) 327 (43.9) 704 (39.8)
Marital status
Married 179 (52.3) 174 (59.4) 185 (47.3) 248 (33.3) 786 (44.4)
Not married 163 (47.7) 119 (40.6) 206 (52.7) 497 (66.7) 985 (55.6)
Intravenous drug user
(IDU)
Yes 0 3 (1.0) 5 (1.3) 19 (2.6) 27 (1.5)
No 342 (100) 290 (99.0) 386 (98.7) 726 (97.5) 1744 (98.5)
Any partners IDU
∗
Yes 5 (1.5) 20 (7.1) 38 (10.6) 102 (15.9) 165 (10.2)
No 335 (98.5) 260 (92.9) 321 (89.4) 539 (84.1) 1455 (89.8)
Ever a commercial sex
worker
∗
Yes 6 (1.8) 30 (10.2) 36 (9.3) 66 (8.9) 138 (7.8)
No 336 (98.3) 263 (89.8) 353 (90.8) 679 (91.1) 1631 (92.2)
Received transfusion
(1985–89)
∗+
Yes 5 (1.5) 3 (1.0) 10 (2.6) 15 (2.0) 33 (1.9)
No 334 (98.5) 290 (99.0) 380 (97.4) 730 (98.0) 1734 (98.1)
HIV subtype
∗
E — 273 (95.5) 318 (88.8) 559 (88.7) 1150 (90.3)
B — 10 (3.5) 22 (6.2) 45 (7.1) 77 (6.0)
E/B — 3 (1.1) 16 (4.5) 12 (1.9) 31 (2.4)
BR/MN/C — 0 2 (0.6) 14 (2.2) 16 (1.3)
Delivery type∗
Cesarean — 33 (11.3) 56 (14.3) 188 (25.2) 277 (19.4)
Vaginal — 260 (88.7) 335 (85.7) 557 (74.8) 1152 (80.6)
Maternal age, years
[mean (range)]
24.5
(15–40) 23.2 (14–40) 24.9 (17–39) 26.3 (15–48) 25.1
(14–48)
Age at 1st intercourse
[mean (range)]
20.0
(13–32) 19.3 (11–35) 19.4 (12–32) 18.6 (7–44) 19.2 (7–44)
Gravidity [mean (range)] 1.8 (1–4) 1.6 (1–4) 1.8 (1–11) 2.1 (1–7) 1.9 (1–11)
Number of sex partners in
past year [mean (range)] 1.0 (1-2) 1.8 (1–200) 1.1 (1–6) 6.9 (1–1428) 3.6
(1–1428)
Number of hours in labor
[mean (range)] — 7.4 (0–28) 10.6 (0–57.9) 14.4 (0–386) 12.0
(0–386)
Duration of membrane
rupture, hours [mean
(range)]
— 3.4 (0–96) 4.0 (0–39.5) 3.0 (0–148) 3.4 (0–148)
HIV viral load at delivery,
log10copies/mL [mean
(range)]
— 4.4 (2.3–6.2) 4.2 (2.3–5.9) 3.8 (2.3–6.0) 4.0
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Table 1: Continued.
Peri-1
(HIV−)
(n = 342)
Peri-1
(HIV+)
(n = 293)
Peri-2
(n = 391)
Peri-3
(n = 745)
Total
(n = 1771)
CD4 count at delivery,
cells/mm3 [mean (range)] — 471
(140–1180)
407
(11–1112) 421 (8–1608) 428
(8–1608)
∗Sample size is decreased due to missing data.
+Thailand began screening blood for HIV in 1989.
Table 2: Odds of being HCV-infected among 1771 pregnant women enrolled in 3 vertical transmission HIV studies in Bangkok, Thailand,
1992–2004.
HCV-infection Adjusted
∗
No. % (n) OR (95% CI) OR (95% CI)
Education
Primary or less 1067 2.3 (24) 1.0 1.0
Greater than primary 704 4.4 (31) 2.00 (1.16–3.44) 1.81 (1.05–3.12)
Marital status
Married 786 2.3 (18) 0.60 (0.34–1.06) 0.72 (0.40–1.29)
Not married 985 3.8 (37) 1.0 1.0
Intravenous drug user (IDU)
Yes 27 74.1 (20) 140 (55.4–351) 126 (48.6–326)
No 1744 2.0 (35) 1.0 1.0
Any partners IDU
+
Yes 165 14.6 (24) 9.74 (5.42–17.5) 7.92 (4.34–14.4)
No 1455 1.7 (25) 1.0 1.0
Ever a commercial sex worker
+
Yes 138 6.5 (9) 2.40 (1.15–5.02) 2.17 (1.03–4.54)
No 1631 2.8 (46) 1.0 1.0
Received transfusion (1985–89)
+
Yes 33 12.1 (4) 4.65 (1.57–13.7) 4.22 (1.41–12.6)
No 1734 2.9 (50) 1.0 1.0
Maternal age, years — — — 0.98 (0.93–1.04) 0.96 (0.90–1.02)
Gravidity — — — 1.17 (0.93–1.47) 1.09 (0.86–1.38)
Number of sex partners in past year — — — 1.00 (0.996–1.005) 1.00 (0.996–1.005)
∗Adjusted for three perinatal studies.
+Sample size is decreased due to missing data.
use (adjusted odds ratio 3.4; 95% CI 1.5–7.4), and having
receivedabloodtransfusion(adjustedoddsratio6.7;95%CI
1.9–23.9). Since HIV-uninfected women were only included
inperi-1,weincludedonlywomeninperi-1whenestimating
the odds of HCV infection by HIV status. This study did not
ﬁnd an association between HIV infection status and HCV
infection (adjusted odds ratio 5.9; 95% CI 0.7–51.0).
For peri-1, all 5 infants born to HIV/HCV-infected
women had samples tested for HCV RNA at 2, 4, and 6
months and no infants were found to be HCV infected. For
peri-2, 12/16 infants had 6-month samples available which
were tested for HCV RNA and 13/16 infants had 18-month
samples available which were tested for HCV antibodies.
All infants had testing from at least one time point and 10
infants were tested at more than one time point. From peri-
2, one infant was HCV-RNA positive at 6 months; additional
testing of a 4-month sample from this infant conﬁrmed that
this infant was HCV-RNA positive. In addition, three infants
were anti-HCV positive by EIA at 18 months. However, only
one of these infants had positive conﬁrmatory testing by
RIBA. For peri-3, 15 infants had serial testing at both 2 and 4
months and 27 infants had testing performed for at least one
time point. No infants were found to be HCV infected.
In summary, among 48 infants tested for HCV who
were born to HIV/HCV coinfected women, two infants
were HCV infected for an HCV transmission rate of 4.2%
(95% 0.51–14.25%). One of these infants was born to a
woman who was infected with HCV genotype 3a and had
an HCV viral load of 764 323 copies/mL and an HIV viral
load of 2092 copies/mL. The mother of this infant received
zidovudine for 4 weeks antenatally and during labor; this
infant was HIV uninfected. The other infant was born to a
woman who was infected with HCV genotype 1a and had
an HCV viral load of >850000 copies/mL and an HIV viral
load of 20 342. The mother of this infant did not receive any
antiretroviral prophylaxis; this infant was HIV infected.Denise J. Jamieson et al. 5
Table 3: HIV/HCV status and clinical characteristics of infants born to 1429 HIV-infected women enrolled in 3 vertical transmission of HIV
studies in Bangkok, Thailand, 1992–2004 (n (%)).
Peri-1
(n = 293)
Peri-2
(n = 391)
Peri-3
(n = 745) Total
HIV status of infant
∗
Infected 68 (24.4) 55 (14.4) 52 (7.5) 175 (12.9)
Uninfected 211 (75.6) 327 (85.6) 646 (92.6) 1184 (87.1)
HCV status of infant
Infected 0 2 (0.5) 0 2 (0.1)
Uninfected 293 (100) 389 (99.5) 745 (100) 1427 (99.9)
Infant gender
Male 136 (46.4) 207 (52.9) 365 (49.0) 708 (49.6)
Female 157 (53.6) 184 (47.1) 380 (51.0) 721 (50.5)
Birthweight
< 2500g 31 (10.6) 31 (7.9) 81 (10.9) 143 (10.0)
≥ 2500g 262 (89.4) 360 (92.1) 664 (89.1) 1286 (90.0)
Gestational age [mean
(range)] 39.4 (28–44) 39.7 (35–45) 38.7 (31–44) 39.1
(28–45)
∗Sample size is decreased due to missing data.
The HIV vertical transmission rate among infants born
to the 1429 HIV-infected women was 12.9% (Table 3). There
was a 9.4% (5/53) HIV transmission rate among HCV-
infected mothers and a 13.0% (170/1306) HIV transmission
rate among HCV-uninfected mothers (P = .445). The odds
of an infant being HIV infected did not diﬀer signiﬁcantly
by the mother’s HCV status neither in unadjusted analyses
(odds ratio 0.70; 95% CI 0.27–1.77), nor in analyses adjusted
for perinatal study (adjusted odds ratio 0.82; 95% CI
0.32–2.12).
4. CONCLUSIONS
HCV infection in pregnancy is emerging as an increasingly
important issue. Due to improved HCV blood screening,
mother-to-child transmission of HCV has now replaced
transfusion-associated transmission as the predominant
mode of spread in children [1]. In this retrospective analysis
of more than 1700 pregnant women in Thailand, most
of whom were HIV infected, we found relatively low
hepatitis C seroprevalence rates. Among the HIV-infected
pregnant women, HCV seroprevalence was 3.8% and active
HCV infection was 3.0%. Among HIV-uninfected pregnant
women, HCV seroprevalence was 0.3%. The low rate of
injection drug use in the population (1.5%) likely accounts
for this relatively low HCV seroprevalence, which is only
slightly higher than many general populations of pregnant
women who are HIV uninfected. (1) In a study conducted
in Thailand from 1993-1994 among a convenience sample
of 120 HIV-infected women, 6.7% were anti-HCV positive
by EIA [12]. In another study in Thailand in 1991, 2.7% of
883womenadmittedtothehospitalwithgynecologicabnor-
malities had HCV antibodies [13]. Among Thai women
reporting injection drug use, higher HCV prevalence rates
have been reported, with 15% of 200 female injection drug
users HCV infected in a recent study [14].
The risk factors for HCV infection identiﬁed, which
included more education, intravenous drug use, having a
partner with a history of injection drug use, ever having
been a commercial sex worker, and having received a blood
transfusion, were similar to risk factors associated with
H C Vi np r i o rs t u d i e s[ 15]. Although the number of HIV-
uninfected women was small in this study, we did not
ﬁnd HIV infection to be a signiﬁcant risk factor for HCV
infection. Asexpected,ahistoryofinjection drugusewasthe
strongest predictor of HCV infection (adjusted OR 126; 95%
CI 48.6–326), similar to other studies among blood donors
which have also identiﬁed injection drug use as a strong risk
factor for HCV infection [15]. There are six major HCV
genotypes,whicharenumbered1–6andsubtypeda,b,andc.
Type 1b is the most common genotype worldwide. Types 1a
and3a,whichwerethepredominantgenotypesinthepresent
study, are largely associated with injection drug use [16, 17].
In the United States, routine HCV screening is recom-
mended for persons with certain high-risk characteristics
(e.g., history of injection drug use or blood transfusion) and
for children born to HCV-infected women [18]. However,
routine screening is not recommended for pregnant women
without other risk factors [19]. U.S. guidelines also recom-
mend that HIV-infected persons be routinely screened for
HCV [20]. In Thailand, although current national guidelines
do not address routine HCV screening or hepatitis testing
for HIV-infected patients, most physicians provide hepatitis
testing for HIV-infected adults with symptoms or risk
factors, and pediatric providers in tertiary care centers often
test HIV-infected children who are at risk. Pregnant women
in antenatalclinics arealsoroutinely screenedforhepatitis B,
but not HCV. HCV treatment is available in Thailand at cost
to patients or to patients with private health insurance.
The HCV perinatal transmission rate among infants
born to HIV/HCV coinfected women in this study was
4.2%. However, due to the small number of HCV-infected6 Infectious Diseases in Obstetrics and Gynecology
women in our sample, the conﬁdence interval was wide. The
estimated frequency of HCV transmission in this current
study is similar to those of two recent multicenter studies
conducted among mostly HIV-uninfected women in the
UnitedStates[21]andE ur ope[22]whichreportedtransmis-
sion rates of 3.6% and 6.2%, respectively. Since HIV-infected
women in this cohort had relatively high CD4 counts at
delivery, it is not clear how generalizable these ﬁndings are
to other cohorts of HIV-infected pregnant women. Although
the published literature has shown a correlation of maternal
HCV viral load and the risk of HCV vertical transmission [4,
23], there were too few HCV mother-to-child transmission
in our study to draw conclusions. However, both HCV-
infected infants born to HIV-infected women had high HCV
viral loads.
ACKNOWLEDGMENTS
The authors wish to thank the TUC laboratory staﬀ for their
outstanding work processing and testing all the specimens,
and Daniel Newman for his extensive assistance with data
management for the study. This study received funding
from the Opportunistic Infections Working Group at the
Centers for Disease Control and Prevention. The ﬁndings
andconclusionsinthisarticlearethoseoftheauthorsanddo
not necessarily represent the oﬃcial position of the Centers
for Disease Control and Prevention.
REFERENCES
[1] E. A. Roberts and L. Yeung, “Maternal-infant transmission of
hepatitis C virus infection,” Hepatology, vol. 36, no. 5B, pp.
S106–S113, 2002.
[ 2 ]G .L .A r m s t r o n g ,A .W a s l e y ,E .P .S i m a r d ,G .M .M c Q u i l l a n ,
W. L. Kuhnert, and M. J. Alter, “The prevalence of hepatitis
C virus infection in the United States, 1999 through 2002,”
Annals of Internal Medicine, vol. 144, no. 10, pp. 705–714,
2006.
[3] V. Papaevangclou, H. Pollack, G. Rochford, et al., “Increased
transmission of vertical hepatitis C virus (HCV) infection
to human immunodeﬁciency virus (HIV)-infected infants of
HIV- and HCV-coinfected women,” The Journal of Infectious
Diseases, vol. 178, no. 4, pp. 1047–1052, 1998.
[4] D. L. Thomas, S. A. Villano, K. A. Riester, et al., “Perinatal
transmission of hepatitis C virus from human immunodeﬁ-
ciency virus type 1-infected mothers,” The Journal of Infectious
Diseases, vol. 177, no. 6, pp. 1480–1488, 1998.
[ 5 ]D .C o n t e ,M .F r a q u e l l i ,D .P r a t i ,A .C o l u c c i ,a n dE .M i n o l a ,
“Prevalence and clinical course of chronic hepatitis C virus
(HCV) infection and rate of HCV vertical transmission in a
cohort of 15,250 pregnant women,” Hepatology, vol. 31, no. 3,
pp. 751–755, 2000.
[6] S. L. Thomas, M.-L. Newell, C. S. Peckham, A. E. Ades, and
A. J. Hall, “A review of hepatitis C virus (HCV) vertical
transmission: risks of transmission to infants born to mothers
withandwithoutHCVviraemiaorhumanimmunodeﬁciency
virus infection,” International Journal of Epidemiology, vol. 27,
no. 1, pp. 108–117, 1998.
[7] L. T. F. Yeung, S. M. King, and E. A. Roberts, “Mother-to-
infant transmission of hepatitis C virus,” Hepatology, vol. 34,
no. 2, pp. 223–229, 2001.
[8] N.Shaﬀer,R.Chuachoowong,P.A.Mock,etal.,“Short-course
zidovudine for perinatal HIV-1 transmission in Bangkok,
Thailand: a randomised controlled trial,” The Lancet, vol. 353,
no. 9155, pp. 773–780, 1999.
[9] N. Shaﬀer, A. Roongpisuthipong, W. Siriwasin, et al., “Mater-
nal virus load and perinatal human immunodeﬁciency virus
type 1 subtype E transmission, Thailand,” The Journal of
Infectious Diseases, vol. 179, no. 3, pp. 590–599, 1999.
[10] A. Teeraratkul, R. J. Simonds, S. Asavapiriyanont, et al.,
“Evaluating programs to prevent mother-to-child HIV trans-
mission in two large Bangkok hospitals, 1999–2001,” Journal
of Acquired Immune Deﬁciency Syndromes,v o l .3 8 ,n o .2 ,p p .
208–212, 2005.
[11] D. L. Thomas, “Mother-infant hepatitis C transmission:
second generation research,” Hepatology,v o l .2 9 ,n o .3 ,p p .
992–993, 1999.
[12] S. Suwanagool, S. Tieangrim, W. Ratanasuwan, S. Mekanan-
tagosol, P. Luengrojanakul, and P. Kunasol, “Seroprevalence of
anti-HCV among HIV-infected persons and general popula-
tion,” Journal of the Medical Association of Thailand, vol. 78,
no. 11, pp. 611–617, 1995.
[13] A. Roongpisuthipong, I. Suphanit, K. Yamaguchi, et al., “The
study of HCV antibody and serologic tests for syphilis in Thai
patients with gynecologic disorders,” Asian Paciﬁc Journal of
Allergy and Immunology, vol. 11, no. 2, pp. 135–139, 1993.
[14] J. Jittiwutikarn, S. Thongsawat, V. Suriyanon, et al., “Hepatitis
C infection among drug users in northern Thailand,” Ameri-
canJournalofTropicalMedicineandHygiene,v ol.74,no .6,pp .
1111–1116, 2006.
[ 1 5 ] E .L .M u r p h y ,S .M .B r y z m a n ,S .A .G l y n n ,e ta l . ,“ R i s kf a c t o r s
for hepatitis C virus infection in united states blood donors,”
Hepatology, vol. 31, no. 3, pp. 756–762, 2000.
[16] P. Simmonds, “Viral heterogeneity of the hepatitis C virus,”
Journal of Hepatology, Supplement, vol. 31, no. 1, pp. 54–60,
1999.
[17] P. Simmonds, “Genetic diversity and evolution of hepatitis C
virus—15 years on,” Journal of General Virology, vol. 85, no.
11, pp. 3173–3188, 2004.
[18] Centers for Disease Control and Prevention, “Recommen-
dations for prevention and control of hepatitis C virus
(HCV) infection and HCV-related chronic disease,” MMWR
Recommendations and Reports, vol. 47, no. RR-19, pp. 1–39,
1998.
[19] American College of Obstetricians and Gynecologists, “ACOG
educational bulletin. Viral hepatitis in pregnancy. Number
248, July 1998 (replaces No. 174, November 1992). American
College of Obstetricians and Gynecologists,” International
J o u r n a lo fG y n e c o l o gy&O b s t e t r i c s , vol. 63, no. 2, pp. 195–202,
1998.
[20] J. E. Kaplan, H. Masur, and K. K. Holmes, “Guidelines
for preventing opportunistic infections among HIV-infected
persons—2002. Recommendations of the U.S. Public Health
Service and the Infectious Diseases Society of America,”
MMWR Recommendations and Reports, vol. 51, no. RR-8, pp.
1–46, 2002.
[21] E. E. Mast, L.-Y. Hwang, D. S. Y. Seto, et al., “Risk factors
for perinatal transmission of hepatitis C virus (HCV) and the
natural history of HCV infection acquired in infancy,” The
Journal of Infectious Diseases, vol. 192, no. 11, pp. 1880–1889,
2005.
[22] P.-A. Tovo, L. Pembrey, and M.-L. Newell, “A signiﬁcant sex—
but not elective cesarean section—eﬀect on mother-to-child
transmission of hepatitis C virus infection,” The Journal of
Infectious Diseases, vol. 192, no. 11, pp. 1872–1879, 2005.Denise J. Jamieson et al. 7
[23] H. Ohto, S. Terazawa, N. Sasaki, et al., “Transmission of
hepatitis C virus from mothers to infants,” The New England
Journal of Medicine, vol. 330, no. 11, pp. 744–750, 1994.